Page last updated: 2024-12-08

uridine diphosphate galactosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

uridine diphosphate galactosamine: isolated from Bacillus megaterium; intermediate in the biosynthesis of galactosamine-6-phosphate polymer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

UDP-alpha-D-galactosamine : A UDP-amino sugar having alpha-D-galactosamine as the amino-sugar component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID161225
CHEMBL ID2092918
CHEBI ID16846
MeSH IDM0146476

Synonyms (18)

Synonym
udp galactosamine
17479-06-0
uridine diphosphate galactosamine
udp-alpha-d-galactosamine
C02467
udp-galactosamine
[(2r,3r,4r,5r,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
AC1Q6SAB ,
CHEMBL2092918
chebi:16846 ,
uracil diphosphate galactosamine
udpgalactosamine
uridine 5'-[3-(2-amino-2-deoxygalactopyranosyl) dihydrogen diphosphate]
[(2r,3r,4r,5r,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl] [[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] hydrogen phosphate
Q27102108
udp-galn
CYKLRRKFBPBYEI-KBQKSTHMSA-N
DTXSID901316536
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
UDP-amino sugar
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
Disease1278231
Infectious disease89579
SARS-CoV Infections28229
SARS-CoV-1 Infection11422
Translation of Structural Proteins1114
Maturation of protein 3a25
SARS-CoV-1 Infection6019
SARS-CoV-2 Infection7720
SARS-CoV-2 Infection19527
Late SARS-CoV-2 Infection Events3418
Viral Infection Pathways72739

Bioassays (1)

Assay IDTitleYearJournalArticle
AID74257The compound was tested for inhibition of the rate of 1 uM UDP-[3H]-GlcNAc import into the lumen of the Golgi membranes.1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Inhibition of UDP-N-acetylglucosamine import into Golgi membranes by nucleoside monophosphates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's2 (20.00)18.2507
2000's3 (30.00)29.6817
2010's1 (10.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.49 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]